To play a one-stop effect, Huayu Pharmaceutical intends to merge with Jianru Pharmaceutical
Reporter Li Yiru Taipei2018/05/08 19:58
Huayu Pharmaceutical (6621-TW) and Jianru Pharmaceutical, both under Jianya (4130-TW), in order to integrate resources, enhance competitiveness, and strengthen the energy of new drug research and development, the two companies will be merged, and Huayu Pharmaceutical will be the surviving company, and Huayu Pharmaceutical will issue new shares for 1 share to merge Jianru Pharmaceutical, which is expected to be the base date of the merger on September 1 this year.
Chen Zheng, chairman of Huayu Pharmaceutical, said that Huayu Pharmaceutical and Jianru are upstream and downstream in the biotechnology and pharmaceutical industry, and if the two parties merge, Huayu Pharmaceutical’s marketing specialty and Jianru’s R&D energy will complement each other, which can not only push forward the existing cooperative projects more effectively, but also quickly find the most internationally competitive products under the one-stop operation, establish an innovative and marketable product pipeline, and enhance the company’s value.
The core of Huayu Pharmaceutical’s operation is close to the clinical end of medical services and product agent marketing, and the outstanding results of ADEPT anti-stick solution are recognized by the original Baxter Healthcare, and the ADEPT anti-stick solution provides all-round protection and reduces the effect of adhesion in abdominal surgery, which is also widely trusted and widely used by clinicians.
In addition, Huayu Pharmaceutical has also cooperated with ITRI in the diagnosis and treatment of cancer with tumor marker DR-70 enzyme immunoassay diagnostic reagent (DR-70) and radiofrequency ablation technology (RFA), and is expected to develop RFA 2.0 into the world in the future.
Jianru Pharma is a specialty drug R&D company specializing in the development of innovative dosage forms, searching for new products (505 B2 new drugs) with patient needs and market competitiveness, including high-tech or patent-related barriers, high-entry barriers to generic drugs, and patented oral solid release control agent technology platform applications. With the R&D expertise of Jianru, Huayu Pharmaceutical has transformed from an agent marketing professional to an internationally competitive R&D pharmaceutical company.
